Companies › OrsoBio
2 active drug programs in 2 registered trials: 2 Phase 1; Other, Metabolic and endocrine; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TLC-6740 | – | Phase 1 | Healthy Subjects | Jan 2027 |
| TLC-1180 | – | Phase 1 | Healthy Participants | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05822544 | TLC-6740 | Phase 1 | Healthy Subjects | Metabolic and endocrine | Jan 2027 |
| NCT07300189 | TLC-1180 | Phase 1 | Healthy Participants | Other | Mar 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.